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Abstract
Hemogenic endothelium (HE) undergoes endothelial-to-hematopoietic transition (EHT) to
generate blood, a process that requires progressive down-regulation of endothelial genes
and induction of hematopoietic ones. Previously, we have shown that the transcription factor
HoxA3 prevents blood formation by inhibiting Runx1 expression, maintaining endothelial
gene expression and thus blocking EHT. In the present study, we show that HoxA3 also pre-
vents blood formation by inhibiting Notch pathway. HoxA3 induced upregulation of Jag1
ligand in endothelial cells, which led to cis-inhibition of the Notch pathway, rendering the HE
nonresponsive to Notch signals. While Notch activation alone was insufficient to promote
blood formation in the presence of HoxA3, activation of Notch or downregulation of Jag1
resulted in a loss of the endothelial phenotype which is a prerequisite for EHT. Taken
together, these results demonstrate that Notch pathway activation is necessary to downre-
gulate endothelial markers during EHT.
Introduction
Hematopoietic stem cells (HSC) originate in the Aorta-Gonad-Mesonephros (AGM) region of
the embryo [1–4]. A subset of endothelial cells lining the aorta undergoes changes to generate
the hematopoietic clusters that line the ventral portion of the aorta [5, 6]. This process is
known as endothelial-to-hematopoietic transition (EHT). EHT requires coordinated downre-
gulation of endothelial lineage genes and upregulation of hematopoietic lineage genes, and
involves interaction between endothelial cells and stroma cells surrounding the aorta [7, 8].
We have shown that HoxA3, a transcription factor of the homeodomain family [9, 10],
blocks EHT by directly inhibiting Runx1 expression [11]. Such a blockade correlates with
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maintenance of endothelial cell phenotype and no appearance of hematopoietic cell pheno-
type. Thus, EHT likely involves a signaling pathway that downregulates endothelial cell gene
expression and orchestrates the acquisition of hematopoietic cell phenotype [11]. During the
search of candidate signaling pathways that regulate EHT, we noted that Jag1 was significantly
upregulated in HE. The Notch pathway is activated when a Notch ligand such as Dll1, Dll3,
Dll4, Jag1, or Jag2 interacts in trans with Notch receptor 1 to 4 on an adjacent cell. Upon this
interaction, the intracellular domain of the receptor is cleaved and translocated to the nucleus
where it activates the CSL complex, resulting in the induction of Notch target genes [12]. Acti-
vation of the Notch pathway becomes more complex when ligands and receptors are both
expressed on the same cell because, under those conditions, ligands can inhibit the receptors
through a phenomenon called cis-inhibition [13–16].
Activation of the Notch pathway is necessary for proper vasculogenesis and angiogenesis in
vivo [17–19] and for blood formation [20–23]. In addition, the requirement of the Notch path-
way for HSC formation varies depending on the stages of EHT. The pathway is absolutely
required at the beginning of EHT and it becomes dispensable when HSC are fully formed [24].
This is corroborated by the observation that mice lacking Jag1 do not develop blood [22]. It
has been recently proposed that Jag1 functions to counteract Dll4 activity during blood devel-
opment [25]. While the studies described above address the necessity of the pathway for blood
formation, it is unclear how regulation of Notch receptors and ligands affect pathway activa-
tion or repression and ultimately EHT.
Here, we identify a new mechanism by which HoxA3 tightly controls blood formation by
inhibiting the Notch pathway in HE. We show that HoxA3 induced up-regulation of Jag1 in
HE that has not yet started blood commitment. This upregulation caused Notch ligand cis-
inhibition and blocked the initiation of blood commitment. Consistent with our model, forced
activation of Notch pathway, either in a ligand-independent fashion or by down-regulation of
Jag1, triggered blood commitment by down-regulating the endothelial cell phenotype, a step
required for the initiation of EHT. These findings suggest that HoxA3 prevents blood commit-
ment through Notch cis-inhibition and identify the Notch pathway as a potential therapeutic
target for blood development in vitro.
Materials and methods
Cell culture
HoxA3-inducible murine ES cells were previously generated, by cassette exchange recombina-
tion in doxycycline-inducible locus [11]. ES cells were co-cultured with MEFs in knockout
DMEM supplemented with 15% FBS, 0.1 mM nonessential amino acids, 2 mM glutamax, pen-
icillin/streptomycin, 0.1 mM β-mercaptoethanol, and 1000 U/mL LIF, at 37˚C in 5% CO2.
Embryoid Bodies (EBs) were differentiated by hanging-drops suspension culture in EB differ-
entiating media (IMDM supplemented with 15% FBS, 200 μg/mL iron-saturated transferrin,
4.5 mM monothiolglycerol, 50 μg/mL ascorbic acid, penicillin/streptomycin, and 2 mM gluta-
max at 37˚C in 5% CO2, 5% O2). At day 4 of differentiation, EBs were treated with doxycycline
(1μM) to induce HoxA3 overexpression. At day 6, EBs were collected, dissociated by using
trypsin at 37˚C for 2–3 min following mechanical dissociation, and immunostained with
Flk1-PE and Ve-cadherin-APC antibodies (S1 Table). Two hundred thousand double-positive
cells were sorted by flow cytometry using FACs Aria III and plated on OP9 stromal cell mono-
layers (50,000 OP9 cells per well pre-plated in 6-well dishes one day prior) in IMDM supple-
mented with 10% FBS, 5 ng/mL VEGF, 40 ng/mL TPO, 40 ng/mL Flt-3 ligand, penicillin/
streptomycin, 2 mM glutamax, with or without doxycycline at 37˚C in 5% CO2. Notch inhibi-
tion was performed with DAPT treatment (20 and 60 μM). For experiments involving Notch
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ligand overexpression, OP9-Dll1 [26] and OP9 control cells were growth-arrested with Myto-
micyn-c treatment (7.5 μg/ml) for 4 hours. OP9 growth arrested cells were plated a day before
co-culture in fresh OP9 media. After co-culture in OP9, cells were harvested by trypsinization
for 1 minute at 37˚C followed by antibody staining.
Plasmids
The pMSCV-hNICD-Ires-GFP was constructed by subcloning a blunted Not1/Ecor1 hNICD
(from NOTCH1 receptor) fragment [27] into pMSCV-ires-GFP. For knock-down experi-
ments, pLKO-Jag1 KD (clone TRCN0000028869, Open Biosystem) was used. Puromycin
resistance was replaced with eGFP using blunt-end cloning.
Retroviral/Lentiviral transduction
Retroviral transduction of pMSCV-ires-GFP, pMSCV-hNICD-ires-GFP and pLKO-Jag1 KD
were performed as reported [11]. Retrovirus and lentivirus were generated by transient trans-
duction of 293T with BioT reagent (Bioland). Supernatant was collected at 24, 48 and 72h after
transfection and virus concentrated with a Sorvall RC6+ (rotor F21S-8X50y) by ultracentrifu-
gation for 3 hours at 47.000g. Retroviral and Lentiviral transduction were performed on day 6
FV sorted progenitors and BEND3 cells.
Quantitative real time RT-PCR (qRT-PCR)
Total RNA was extracted with Trizol LS (Invitrogen) and cDNA generated with iScript reagent
(BioRad) according to protocol. PCR was performed using TaqMan mix (Life Technologies)
on a 7600 RT-PCR System from Applied Biosystems. Probes purchased from Applied Biosys-
tems are listed in S1 Table.
Antibody staining
Flow cytometry was performed by staining with specific anti-mouse antibodies. Analysis was
performed using FACS ARIA III and data analyzed using FlowJo software. For Immunofluo-
rescence staining, cells were fixed in 4% PFA for 4 min following by antigen retrieval in Tris-
EDTA buffer pH 9.0 and permeabilized as reported in 0.2% triton for 15 min [11]. Cells were
incubated overnight with primary antibodies Jag1, VE-Cadherin ad activated-NICD. Pictures
were acquired using 20X magnitude lens on Leica TCS SP Upright Confocal Microscope and
40X lens on Nikon Eclipse Ci fluorescent microscope. All antibodies used are listed in S1
Table.
Western blot
293T cells were transfected with pMSCV-hNICD-iresGFP or pMSCV-iresGFP, proteins were
extracted with RIPA Buffer (Millipore # 20–188). After blotting membranes were stained with
Ponceau S and probed with anti-Myc-tag for NICD detection. Cytoplasmic proteins from
Bend3 cells transfected with pLKO Jag1-KD or pGIPZ-GFP and Day 6 FV progenitors were
extracted using NE-PER extraction kit (Thermo-Scientific #78833). After protein separation
and blotting (Millipore #456–1096 and # 170–4158) membranes were probed using Jag1 spe-
cific antibody followed by specific secondary antibody. Membranes were imaged using BioRad
Chemi Doc Imaging system. All antibodies used are listed in S1 Table.
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Statistical analysis
Data were analyzed using GraphPad Prism software (La Jolla California, USA). Data obtained
from 6 hours, 5 days of HoxA3 up-regulation experiments and DAPT treatment on the expres-
sion of Notch target genes in BEND3 cells were analyzed with unpaired, two-tailed t-test. Inde-
pendent data sets were analyzed by two-way ANOVA using HoxA3 regulation (Con vs
HoxA3) and treatment (DMSO/DAPT, Con/NICD transduction, OP9 Con/ OP9 Dll1) as
between-subject followed by Fisher’s LSD post hoc tests. One-way ANOVA was performed to
analyze the effect of Jag KD on Con and HoxA3 upregulation. Significance was set at p<0.05.
Results
HoxA3 upregulates Jag1 but does not activate the Notch pathway
We have previously reported an experimental model that recapitulates blood formation from
EHT using embryonic stem cell differentiation. This model takes advantage of the ability of
HoxA3 to block blood formation from HE, providing a synchronized and homogeneous popu-
lation of HE [11] (S1A Fig). Under these conditions, we performed transcriptional analysis in
HE upon brief HoxA3 up-regulation [11] (Fig 1A). In this analysis, we found that the Notch
ligand Jag1 was upregulated 2.5 fold after a 6 hours induction of HoxA3, suggesting that
HoxA3 controls Jag1 expression. Other Notch ligands such as Dll1 and Dll3, the Notch1 recep-
tor, and the Notch target gene Hes1 were not upregulated (Fig 1B).Two days induction of
HoxA3 resulted in strong upregulation of Jag1 at protein levels (Fig 1C). This result was unex-
pected since the effect of these molecules on blood formation is opposite: HoxA3 blocks blood
formation [11] whereas Jag1 promotes blood formation [22]. This paradox was not due to a
selective effect of HoxA3 on vein commitment nor its action on arterial commitment as there
were no changes in the expression of the arterial markers CXCR4, CD44 and Efnb2, or in the
expression of venous markers Ephb4 in the endothelial compartment (S1B and S1C Fig).
Next, we determined if the up-regulation of Jag1 expression by HoxA3 correlated with acti-
vation of the Notch pathway. This was done by culturing the HE on OP9 stroma cells for a lon-
ger period of time (Fig 1D). Taking advantage of the property of HoxA3 to repress blood
formation during EB differentiation, we enriched HE in the endothelial compartment and
modeled EHT in vitro using the OP9 co-culture. The starting population of endothelial cells
expressed CD31 and Tie2 (not shown) as well as Flk1 and Ve-cadherin (S1A Fig). When the
HE cells were grown on OP9, and upon downregulation of HoxA3, EHT occurred and blood
was formed. However, if HoxA3 overexpression was maintained, then the HE cells remained
in their endothelial state (S1D Fig) [11].
Under these conditions, we were able to evaluate the function of the Notch pathway during
EHT. In the following experiments, we co-cultured HoxA3 induced cells during EB differenti-
ation on OP9 for 5 days with or without HoxA3 up-regulation, then separated the EB-derived
cells from the OP9 and performed qPCR analysis. Upon HoxA3 induction, both Jag1 mRNA
levels and protein were significantly up-regulated in endothelial cells (Fig 1E and 1F). As
shown by immunofluorescence (Fig 1E), Jag1 expression was present in every endothelial cell
when HoxA3 was upregulated. Jag2 and Dll4 were significantly down-regulated whereas Dll1
and Dll3 were not. While there were no significant changes in the Notch receptors, the glyco-
syltransferase enzymes manic (Mfng) and lunatic (Lfng) fringe were downregulated (Fig 1F).
These enzymes increase the affinity of Notch receptors to Dll1 ligand in trans [28] and thus,
their downregulation is associated with lower ability of the endothelial cells to receive Notch
signals. Under the same conditions, the Notch target genes Hey2, Hey1 and Hes1 showed no
apparent activation in endothelial cells (Fig 1F). Such lack of activation was not due to the
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Fig 1. HoxA3 up-regulates the Notch ligand Jag1 but does not activate the Notch pathway. A) Experimental procedure (see methods for
details). B) Gene expression levels of the Notch pathway components in purified endothelial cells (Flk1+/VE-Cadherin+) derived from day 6
control EBs (white bars) or upon 6 hours of HoxA3 up-regulation (black bars). C) Western blot analysis using Jag1 specific antibody in purified
endothelial cells (Flk1+/VE-Cadherin+) derived from day 6 control EBs (white bars) or upon 2 days of HoxA3 up-regulation (black bars) D)
Experimental procedure (see methods for details). E) Immunofluorescence staining for Jag1 (red), VE-Cadherin (green) and Hoechst (blue)
showing adherent endothelial clusters growing in Control (Con) or HoxA3 overexpression (HoxA3), derived from endothelial cells (Flk1+/VE-
cadherin+) and co-cultured for 5 days on OP9 cells. Bar: 100 μM. F) Gene expression levels of Notch ligands Jag1/Jag2/Dll1/Dll3/Dll4, Notch
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inability of HE cells to respond to Notch signals [24] but rather to the inability of OP9 to effi-
ciently promote Notch activation [23, 29].
To test whether the increased expression of Jag1 in endothelial cells had a biological effect
in trans, we evaluated the expression of Notch target genes in the OP9 stromal cells. We found
that there was induction of the Notch pathway as measured by Hey2 upregulation only when
OP9 cells were co-cultured with endothelial cells overexpressing HoxA3, (S1E Fig). Together,
these data suggested that HoxA3 induces Jag1 up-regulation in endothelial cells which in turn
induced Notch activation in trans (i.e., on OP9 cells) but not in cis (i.e., on endothelial cells).
Repression of EHT by HoxA3 is not affected by inhibition of the Notch
pathway
Next, we tested whether the blockade of blood formation was secondary to HoxA3-dependent
Notch activation. To test this possibility, we differentiated EBs and plated them on OP9 cells
with or without HoxA3 up-regulation and in the presence or absence of the Notch pathway
inhibitor DAPT (Fig 2A). As expected up-regulation of HoxA3 resulted in repression of blood
formation as measured by the lack of CD41 and CD45-expressing cells (Fig 2B, S2 Fig, gating
strategies). Notch pathway inhibition was not able to restore blood formation in cells overex-
pressing HoxA3 nor did result in any changes in control cells (Fig 2B, S3A Fig) while still
repressing efficiently Notch target genes (S3B Fig). A higher DAPT concentration had the
same effect (data not shown). In addition, Notch inhibition did not affect the differentiation
into myeloid cells (i.e., cells expressing CD45/Gr1) nor the arterial commitment of the cells (i.
e., Ve-Cadherin+/Cxcr4+ and Ve-Cadherin+/CD44+) (S3C Fig). More importantly, DAPT
treatment significantly increased the frequency of Flk1+ Ve-cadherin+ endothelial cells (Fig
2C). These data showed that Notch inhibition by itself cannot promote blood formation, ruling
out the possibility that the blockade of blood formation is due to HoxA3-dependent Notch
activation.
Notch activation down-regulates the endothelial phenotype of HE but
does not promote blood formation
Next, we tested whether the blockade of blood formation was due to HoxA3-dependent repres-
sion of Notch activation. To do this, we forced activation of Notch in a ligand-independent
fashion using NICD transduction (Fig 3A). NICD up-regulation was assessed by immunoblot-
ting (S4A Fig) and by the expression of Notch target genes Hey1, Hey2 and Hes1 (Fig 3B).
Hematopoietic clusters were visible in control and NICD-transduced group but could not be
detected in NICD-transduced group when HoxA3 was overexpressed (Fig 3C). Thus, the
blockade of blood formation itself was not due to HoxA3-dependent inhibition of Notch.
Blood formation involves not only induction of hematopoietic gene expression but also
down-regulation of endothelial gene expression. Therefore, we next examined the effect of
Notch activation on the endothelial phenotype. Induction of the Notch pathway in cells over-
expressing HoxA3 resulted in a significant decrease in the frequency of Fkl1+/Ve-Cadherin+
endothelial cells (Fig 3D and 3E). Analysis of the frequency of PECAM expression, an addi-
tional endothelial marker, showed the same decrease (S4B Fig). Surprisingly, the decrease in
frequency of endothelial cells did not correspond with an increase of hematopoietic cells as
receptors Notch1 to Notch4, cofactors Lfng (lunatic fringe) Mfng (manic fringe) and target genes Hes1/Hey2/Hey1 on purified control cells (white
bars) or cells overexpressing HoxA3 (black bars) derived from endothelial cells (Flk1+/VE-cadherin+) co-cultured for 5 days on OP9 cells. *:
p<0.05. Detailed statistical analysis is reported in S2 Table.
https://doi.org/10.1371/journal.pone.0186818.g001
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shown by CD41, CD45 (Fig 3D, S4C Fig), Ter119 and Gr1 expressing cells (S4D Fig), which
would be expected if EHT had occurred. Therefore, the decrease in endothelial cell phenotype
was not due to blood formation. The lack of blood formation in presence of NICD was not a
consequence to increased apoptosis of precursor cells (S4E Fig) nor was due to differentiation
of HE into smooth muscle cells. In fact, while up-regulation of Notch pathway resulted in
Fig 2. Repression of EHT by HoxA3 is not affected by inhibition Notch pathway. A) Experimental procedure, Endothelial Derived Cells (ENDO). B)
Representative flow cytometric profile of endothelial surface markers Flk-1/Ve-Cadherin and hematopoietic surface markers c-Kit/CD41, and c-Kit/CD45 on
200,000 EB-derived Flk1+/VE-cadherin+ cells without or with HoxA3 overexpression and co-cultured on OP9 for 5 days in the presence or absence of the
Notch inhibitor DAPT (20 μM). C) Frequency of endothelial surface markers Flk-1+/Ve-Cadherin+ in EB-derived cells. *: p<0.05; **: p<0.01. Two way ANOVA
analyses of Flk-1+/Ve-Cadherin+, CD41+ and CD45+ frequencies are reported on S3 Table.
https://doi.org/10.1371/journal.pone.0186818.g002
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differentiation into vascular smooth muscle cells in control cells [30] (measured as αSMA Fig
3F), this differentiation was inhibited in HoxA3 overexpressing cells. The lack of blood cells
was rather due to inability of Notch signaling to overwrite HoxA3 function and induce expres-
sion of key hematopoietic transcription factors. In fact, when HoxA3 was up-regulated,
hematopoietic markers Runx1, Pu.1 and Gata1 were still significantly down-regulated and the
activation of the Notch pathway did not induce their expression (Fig 3F). Thus, we concluded
that HoxA3 inhibits Notch pathway activation in HE and this maintains the endothelial cell
phenotype.
Notch signaling in trans does not rescue HoxA3-mediated inhibition of
Notch
Next, we examined whether Notch ligands in trans could activate Notch signaling in HoxA3-o-
verexpressing cells. To test this hypothesis, we exposed HE to OP9 overexpressing the Notch
ligand Dll1. After 5 days of co-culture, HE-derived cells were analyzed for blood formation
and for Notch pathway activation (Fig 4A). As shown in Fig 4B and 4C, strong Notch signal in
trans could not promote blood formation in the presence of HoxA3 overexpression as mea-
sured by the frequency of CD41+ and CD45+ cells, in contrast to control cells in which strong
Notch signal could increase the frequency of hematopoietic cells (Fig 4C). As expected, no
changes in the frequency of endothelial cell were observed (S5A Fig) suggesting that the Notch
pathway could not be activated despite the availability of Notch ligands in trans. This possibil-
ity was corroborated by analysis of the expression of Notch target genes. Hes1 and Hey2 were
induced by OP9-Dll1 in control cells and this induction was greatly diminished by HoxA3
overexpression (Fig 4D). Finally, we observed a decrease in the number of cells expressing
nuclear NICD when HoxA3 was upregulated compared to control cells in the co-culture sys-
tem using OP9-Dll1 (Fig 4E).
Downregulation of Jag1 in HE prevents HoxA3-dependent Notch
pathway cis inhibition
Since addition of Notch ligands in trans did not overcome the inhibitory effect of HoxA3 on
the Notch pathway, we postulated that such inhibition was secondary to the presence of high
levels of Jag1 on the HE that would then inhibit Notch signaling in cis. To test this possibility,
we down-regulated Jag1 expression upon transduction of the cells with shRNA specific for
Jag1. This resulted in a significant decrease in Jag1 expression both at mRNA level and protein
level (Fig 5A and 5B). When HE cells were co-cultured on OP9, there was a significant down-
regulation of the endothelial markers Flk-1 and Ve-Cadherin in the presence of HoxA3 over-
expression (Fig 5C). Importantly, Jag1 down-regulation was not sufficient to trigger blood for-
mation in control cells nor in HoxA3 overexpressing cells consistent with the claim that Notch
determines the endothelial phenotype but does not drive by itself blood formation (S5B Fig).
Fig 3. Notch activation down-regulates the endothelial phenotype of the hemogenic endothelium but does not
promote blood formation. A) Experimental procedure, Endothelial Derived Cells (ENDO). B) Gene expression levels in
purified NICD-transduced, GFP-positive cells co-cultured with OP9 for 5 day without or with doxycycline-induced HoxA3
overexpression. HoxA3, Notch pathway components hNotch1, Hes1, Hey1, Hey2 are shown. C) Representative images of
200,000 Flk1+/VE-cadherin+ cells obtained from day 6 EBs, transduced with pMSCV-iresGFP (CON) or with pMSCV-
hNICD1-IresGFP and co-cultured on OP9 for 5 days in absence (CON) or presence (HoxA3) of HoxA3 overexpression. D)
Representative flow cytometric profile of endothelial surface markers Flk-1/Ve-Cadherin and hematopoietic surface markers
c-Kit/CD41, and c-Kit/CD45 of GFP+ gated cells from the same culture as in B, C. E) Frequency of endothelial surface
markers Flk-1+/Ve-Cadherin+. F) Gene expression levels as in B of hematopoietic gene markers, Pu.1, Runx1, Gata1, and
smooth muscle actin on GFP+ control (white bars) or HoxA3-induced (black bars) GFP+ cells are plotted. *: p<0.05.
Statistical analysis is reported on S4 Table.
https://doi.org/10.1371/journal.pone.0186818.g003
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In addition, strong Notch signals in trans (Op9-Dll1 co-culture), while unable to induce blood
formation (not showed), induced an increase of Notch target genes even if HoxA3 was overex-
pressed confirming that Jag1 up-regulation in HE was cis-inhibiting the Notch pathway (Fig
5D).
Discussion
Cell to cell communication between the endothelium and the surrounding stromal cells is cru-
cial for the generation of HSCs [8, 31, 32]. The Notch pathway plays a central role in this com-
munication. It has been proposed that the stroma sends Notch signals to induce Runx1 [8, 20],
which in the dorsal aorta marks the initiation of blood formation [33, 34]. We have previously
shown that HoxA3 in the endothelium represses Runx1 expression and times the initiation of
blood commitment [11]. In the current paper, we show that activation of Notch causes down-
regulation of endothelial genes expression that is needed for EHT. More importantly, our data
demonstrate that HoxA3 expression inhibits Notch pathway to maintain endothelial gene
expression in the HE, preventing EHT. Such inhibition of the Notch pathway that maintains
the endothelial phenotype of HE, results from a cis mechanism, i.e., up-regulation of Jag1 in
these cells induced by HoxA3.
Our findings imply that the role of Notch is linked to regulation of the endothelial pheno-
type. We found that HE expresses all the components for Notch signaling and therefore is sus-
ceptible to regulation by this pathway. When HoxA3 is up-regulated there is a concomitant
up-regulation of Jag1. The presence of this ligand on the same cells that express Notch recep-
tors leads to down-regulation of Notch signaling and this maintains endothelial protein
expression. In contrast, when HoxA3 is down-regulated, Jag1 expression is decreased and this
relieves Notch cis inhibition, allowing cells to receive Notch signals required to initiate EHT.
Such a claim is consistent with the observation that blocking Notch activity did not lead to an
increase in blood formation [35]. Our findings are also in line with a report showing that
Notch activation is required to proceed with the stage of EHT [24], a stage characterized by
decreased HoxA3 expression and increased Runx1 expression.
Our results reveal cis-inhibition of the Notch pathway by high expression of the Notch
ligand Jag1 on the responding HE as an important regulatory mechanism of EHT. Notch cis-
inhibition was initially reported in Drosophila [16]. Our findings are consistent with a previ-
ous report proposing an inhibitory function of Jag1 in EHT [25]. In our system, we show that
when Jag1 is downregulated, endothelial markers are downregulated, consistent with initiation
of EHT, but this is not sufficient for blood formation. This fine mechanism may be sensitive to
the timing of Jag1 deletion. In our experiment endothelial cells were fully developed prior
downregulation of Jag1, while in vivo experiments, Jag1 was deleted throughout development
[25, 36].
Fig 4. Notch signaling in trans does not rescue HoxA3 mediated inhibition of Notch. A) Experimental
procedure B) Representative flow cytometric profile of endothelial surface markers Flk-1/Ve-Cadherin and
hematopoietic surface markers c-Kit/CD41, and c-Kit/CD45 obtained from 200,000 EB-derived Flk1+/VE-
cadherin+ cells and co-cultured on OP9 control (CON) or OP9 overexpressing Dll1 (OP9-Dll1) for 5 days in Control
or HoxA3-overexpressing HE cells. C) Quantification of frequencies of hematopoietic surface markers (CD41,
CD45) of the same cell as in B. D) Gene expression levels of the Notch pathway target genes (Hes1, Hey1, Hey2)
and hematopoietic gene markers (PU.1, Runx1, Gata1) on control (white bar) or HoxA3-overexpressing (black
bars) HE cells co-cultured on OP9 controls (CON) or OP9-DLL1 for 5 days (Flk1+/VE-cadherin+ and CD41+/c-Kit+
cells were pulled together). E) Iimmunofluorescence staining for activated Notch1 (NICD-red), VE-Cadherin
(VECad-green) and Hoechst (blue) showing adherent endothelial clusters growing in Control (Con) or HoxA3
overexpression (HoxA3), derived from endothelial cells (Flk1+/VE-cadherin+) co-cultured on OP9-DLL1 cells *:
p<0.05. Statistical analysis is reported on S5 Table.
https://doi.org/10.1371/journal.pone.0186818.g004
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Fig 5. Forced down-regulation of Jag1 in endothelial cells removes Notch pathway cis inhibition by HoxA3 and initiates EHT. A) Jag1 RNA
expression level in Bend3 cells infected with empty vector (Con) or Jag1 shRNA (Jag1 KD). B) Western blot using specific antibody against Jag1 and GAPDH
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Since activation of the Notch pathway by strong Dll1 signal in trans is capable of promoting
EHT but activation of Notch alone is not, we concluded that EHT needs activation of several
Notch receptors achieved through signals delivered by Dll1 in trans. In contrast, Notch 1 alone
would promote down-regulation of endothelial markers. In our experiments, the Notch path-
way by itself was insufficient to promote EHT because HoxA3-dependent Runx1 repression, is
dominant [1, 11, 37]. In other words, activation of the Notch pathway while Runx1 is inhibited
promoted the HE to an intermediate stage in which the cells had lost their endothelial charac-
teristics but were not able to acquire the hematopoietic signature.
Based on our data, we propose a model to explain EHT as a regulated process triggered by
proper communication between the HE and the stroma, and involving down-regulation of
endothelial genes and up-regulation of the hematopoietic genes (Fig 6). In our model, when
HoxA3 is up-regulated in the endothelium, it induces Jag1 expression on the same cells caus-
ing Notch ligand cis inhibition. This inhibition prevents cells from losing their endothelial
in Bend3 cells infected with empty vector (pGIPZ) or Jag1 shRNA (Plko.1 Jag1). C) Frequency of Flk1+/VE-cadherin+ cells obtained from day 6 EBs,
transduced with empty vector (CON) or with shRNA-Jag1-GFP (JKD) and co-cultured on OP9 for 5 days in Control (Con) or HoxA3 overexpression. D) Gene
expression levels of Notch pathway components Hes1, Hey1, Hey2 from purified control (white bar) or HoxA3-overexpressing cells (black bars), transduced
with empty vector (CON) or with shRNA-Jag1-GFP (JKD) and co-cultured on OP9-DLL1 for 5 days. Graphs in panel D show one representative experiment
with triplicate measurements. *: p<0.05; **: p<0.01; ***: p<0.001. Statistical analysis is reported on S6 Table.
https://doi.org/10.1371/journal.pone.0186818.g005
Fig 6. Proposed model. A) Illustration of ligand cis inhibition in the hemogenic endothelium. HoxA3 dependent Jag1 overexpression in cis interacts with
Notch receptors, inhibiting Notch ligand in trans to interact with the receptor. When HoxA3 is withdrawal the pathway is activated in trans and Runx1 can be
induced in the hemogenic endothelium. B) Effect of HoxA3 on Notch pathway. HoxA3 upregulates Jag1 to inhibit the Notch pathway. The pathway in turn will
promote downregulation of endothelial specific transcripts, and initiate the EHT.
https://doi.org/10.1371/journal.pone.0186818.g006
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phenotype. When HoxA3 is down-regulated, then Notch communication with the stroma can
be properly established triggering down-regulation of endothelial markers and expression of
hematopoietic markers, and this results into blood formation. Our model identifies HoxA3 as
key regulator of Notch signaling and as a potential target for the modulation of blood
formation.
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S1 Fig. A) Representative flow cytometric profile of endothelial surface markers Flk-1/Ve-
Cadherin and hematopoietic surface markers c-Kit/CD41, of 10000 cells obtained from disso-
ciated day 6 EBs treated with or without Dox at day 4 of differentiation. B) Representative flow
cytometric profile and frequency quantification of arterial surface markers Ve-Cadherin/
CD44 and Ve-Cadherin/CXCR4 on 200,000 EB-derived Flk1+/VE-cadherin+ cells without or
with HoxA3 overexpression and co-cultured on OP9 for 5 days. C) Gene expression levels in
purified endothelial cells co-cultured with OP9 for 5 day without or with doxycycline-induced
HoxA3 overexpression. Arterial, EfnB2 and vein markers EphB4 are plotted. D) Representa-
tive flow cytometric profile and frequency quantification of hematopoietic surface markers c-
Kit/CD41, and c-Kit/CD45 on 200,000 EB-derived Flk1+/VE-cadherin+ cells without or with
HoxA3 overexpression and co-cultured on OP9 for 5 days E) Assessment of Notch pathway
activation on OP9 cells alone (left) or purified OP9 cells after co-culture with Flk1+/VE-cad-
herin+ without or with HoxA3 overexpression (right). Notch target genes Hes1 and Hey2 are
plotted. Where present asterisks () identify significant paired two-tailed T test ( p<0.05). Sta-
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S2 Fig. Representative flow-cytometric profile of PE and PECy7 isotype controls and
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S3 Fig. A) Quantification of frequencies of hematopoietic surface markers (ckit-CD41, ckit-
CD45) on 200,000 EB-derived Flk1+/VE-cadherin+ cells without or with HoxA3 overexpres-
sion and co-cultured on OP9 for 5 days in the presence or absence of the Notch inhibitor
DAPT (20μM) B) Evaluation of Notch pathway inhibition (calculated as inhibition of Notch
target genes Hes1, Hey1, Hey2, Hes6) on endothelial cells (BEND3) treated with 20μM of
DAPT or DMSO (CON). C) Frequency quantification of 200,000 cells Flk1+/VE-cadherin+
obtained from day 6 EBs and co-cultured on OP9 for 5 days with or without HoxA3 overex-
pression and treated without (DMSO/CON) or with 20μM of DAPT. Hematopoietic surface
markers Gr1-CD45 and arterial/vein Ve-Cadherin, CXCR4 and CD44 and are plotted. Statisti-
cal analysis is reported on S3 Table.
(PDF)
S4 Fig. A) Western blot analysis and Ponceau S staining of the indicated proteins (cMyc-
NICD and GAPDH) and total loading protein, respectively, in 293T cells transfected with
pMSCV-hNICD-ires GFP plasmid (NICD-1/NICD-2), backbone vector pMSCV-ires GFP
(CON) and non-viral infection (NVI). B) Frequency quantification of endothelial markers
VeCadherin and Pecam (CD31), from gated GFP positive cells transduced with pMSCV-
iresGFP (CON) or with pMSCV-hNICD1-IresGFP (NICD) and co-cultured on OP9 for 5
days in absence (CON) or presence (HoxA3) of HoxA3 overexpression. C) Quantification of
frequencies of hematopoietic surface markers ckit, CD41, CD45, and D) representative flow
cytometric profile of myeloid markers CD45, Gr1 and Ter119 on 200,000 cells Flk1+/VE-
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cadherin+ obtained from day 6 EBs, transduced with pMSCV-iresGFP (CON) or with
pMSCV-hNICD1-IresGFP (NICD) and co-cultured on OP9 for 5 days in absence (CON) or
presence (HoxA3) of HoxA3 overexpression. E) Frequency quantification and representative
flow cytometric profile, of 200,000 cells Flk1+/VE-cadherin+ obtained from day 6 EBs, trans-
duced with pMSCV-iresGFP (CON) or with pMSCV-hNICD1-IresGFP (NICD) and co-cul-
tured on OP9 for 5 days in absence (CON) or presence (HoxA3) of HoxA3 overexpression.
Viability markers PI and Annexin V are plotted. Post-hoc analysis are reported as asterisks ()
alone represents significant differences compared to CON/Dox-,  p<0.05, and bars represents
significant differences () between indicated groups, p<0.05. Statistical analysis is reported on
S4 Table.
(PDF)
S5 Fig. A) Quantification of frequencies of endothelial surface markers Flk-1+/Ve-Cadherin
+ obtained from 200,000 EB-derived Flk1+/VE-cadherin+ cells and co-cultured on OP9 con-
trol (CON) or OP9 overexpressing Dll1 (OP9-Dll1) for 5 days in Control or HoxA3-overex-
pressing HE cells. B) Quantification of frequencies of hematopoietic surface markers (cKit-
CD41, cKit-CD45) on cells obtained from day 6 EBs, transduced with empty vector (CON) or
with shRNA-Jag1-GFP (JKD) and co-cultured on OP9 for 5 days in Control (Con) or HoxA3
overexpression.
(PDF)
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(PDF)
S2 Table. Referred to Fig 1 and S1 Fig. A) Two tails T-test analysis of Notch components on
control endothelial cells (CON) compare to endothelial cells derived from 6 hours upregula-
tion of HoxA3 in D6 total EBs (HoxA3) B) Two tails T-test analysis of Notch components
endothelial derived cells (EDC) co-cultured with OP9 for 5 days without (CON) or with
HoxA3 overexpression.
(PDF)
S3 Table. Referred to Fig 2 and S3 Fig. 2-way ANOVA analysis of endothelial derived cells
co-cultured with OP9 for 5 days without (CON) or with HoxA3 overexpression and treated
without (DMSO) or with (DAPT) Notch inhibitor.
(PDF)
S4 Table. Referred to Fig 3 and S4 Fig. 2-way ANOVA analysis of endothelial derived cells
transduced with pMSCV-NICD-ires GFP (NICD) or pMSCV-iresGFP (CON) and co-cultured
with OP9 for 5 days without (CON) or with HoxA3 overexpression.
(PDF)
S5 Table. Referred to Fig 4 and S5 Fig. 2-way ANOVA analysis on endothelial derived cells
co-culture with OP9-CON vs OP9-Dll1 for 5 days without (CON) or with HoxA3 overexpres-
sion.
(PDF)
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transduced with pGIPZ (CON) or plKO.1-Jag1 KD-ires GFP (JAG KD) and co-cultured with
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